Aridis' pan-coronavirus, inhaled monoclonal antibody cocktail ar-701 is protective in non-human primates

Ar-701 is effective in vitro against sars-cov-2 omicron subvariants, including ba.4 and ba.5 los gatos, calif. , aug. 10, 2022 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that inhaled treatment of its fully human monoclonal antibody cocktail ar-701 resulted in no detectable sars-cov-2 virus in the lungs of infected rhesus macaques, and protected their lungs from disease.
ARDS Ratings Summary
ARDS Quant Ranking